436
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Travel vaccines: current practice and future aspects

&
Pages 527-530 | Published online: 09 Jan 2014

References

  • Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA298(18), 2155–2163 (2007).
  • WHO. Progress in global measles control and mortality reduction, 2000–2006. Wkly Epidemiol. Rec.82(48), 418–424 (2007).
  • Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet367(9526), 1926–1936 (2006).
  • Grassly NC, Wenger J, Durrani S et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case–control study. Lancet369(9570), 1356–1362 (2007).
  • Steinberg EB, Bishop R, Haber P et al. Typhoid fever in travelers: who should be targeted for prevention? Clin. Infect. Dis.39, 186–191 (2004).
  • Angell SY, Behrens RH. Risk assessment and disease prevention in travelers visiting friends and relatives. Infect. Dis. Clin. North Am.19(1), 49–65 (2005).
  • Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect. Dis.5(10), 623–628 (2005).
  • Levine MM, Ferreccio C, Black RE et al. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin. Infect. Dis.45(Suppl. 1), S24–S28 (2007).
  • Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0–18 years – United States, 2008. MMWR Morb. Mortal. Wkly Rep.57, Q1–Q4 (2008).
  • Wilder-Smith A, Hill DR, Freedman DO. The revised International Health Regulation (2005): impact on yellow fever vaccination in clinical practice. Am. J. Trop. Med. Hyg.78(3), 359–360 (2008).
  • Belsher JL, Gay P, Brinton M et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine25(50), 8480–8485 (2007).
  • McMahon AW, Eidex RB, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine25(10), 1727–1734 (2007).
  • Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans. R. Soc. Trop. Med. Hyg.101(10), 967–971 (2007).
  • Khromava AY, Barwick Eidex R, Weld LH et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine23(25), 3256–3263 (2005).
  • Barwick R; Eidex for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination (letter). Lancet364(9438), 936 (2004).
  • Spira A. Yellow fever vaccine as a vehicle to better travel medicine. J. Travel Med.12(6), 303–305 (2005).
  • Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int. J. Antimicrob. Agents21(2), 102–106 (2003).
  • WHO. Health conditions for travellers to Saudi Arabia for the pilgrimage to Mecca (Hajj). Wkly Epidemiol. Rec.82(44), 384–388 (2007).
  • Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis.6, 361–373 (2006).
  • Mütsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988–2004. Clin. Infect. Dis.42(4), 490–497 (2006).
  • Marfin AA, Barwick Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect. Dis. Clin. N. Am.19(1), 151–168 (2005).
  • Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis.188(8), 1213–1230 (2003).
  • Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet370(9602), 1847–1853 (2007).
  • Rupprecht CE, Gibbons RV. Clinical practice. Prophylaxis against rabies. N. Engl. J. Med.351(25), 2626–2635 (2004).
  • Joint Committee on Vaccination and Immunisation. Tuberculosis. ln: Immunization Against Infectious Disease. Salisbury DM, Ramsay M, Noakes K (Eds). Department of Health, London, UK 391–408 (2006).
  • Linhares AC, Velazquez FR, Perez-Schael I et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled Phase III study. Lancet371(9619), 1181–1189 (2008).
  • Andre FE. Recommended travel vaccines: from “travel vaccine” to universal vaccination – the hepatitis A story. In: Travel Medicine: Tales Behind the Stories. Wilder-Smith A, Schwartz E, Shaw M (Eds). Elsevier, Oxford, UK 47–57 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.